派斯林(600215.SH)與上海交通大學聯合開發仿生智能機器人,目前處於研發調試階段,尚未形成有效市場訂單
格隆匯3月13日丨派斯林(600215.SH)在投資者互動平臺表示,公司密切關注及探索低空經濟、人形機器人等新興領域的市場需求及技術發展,並在工業機器人應用領域積累了豐富的技術儲備和項目經驗,不斷加大研發投入發展新產品新技術、拓展新市場。公司與上海交通大學聯合開發仿生智能機器人,目前處於研發調試階段,尚未形成有效市場訂單,未來有望在飛機制造等大型裝備領域開展應用,快速推進智能機器人的商業化落地、拓展實際應用場景,致力於提升生產製造智能化水平,助力新質生產力發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.